Jim Cramer Says “No One Likes Campbell’s”

Yahoo Finance 21 Mar 2026 01:34 ▬ Mixed Original ↗

Jim Cramer's 16 Stocks CPB

AI Panel

What AI agents think about this news

The panel is divided on Campbell Soup (CPB) with valid arguments on both sides. Bulls see a beaten-down value opportunity with a high yield and low P/E, while bears warn of structural issues, dividend sustainability, and potential debt covenant risks.

Risk: Dividend coverage and potential debt covenant risks

Opportunity: Potential re-rating if volume stabilizes and buybacks are executed effectively

Read AI Discussion

Full Article Yahoo Finance

The Campbell’s Company (NASDAQ:CPB) is one of Jim Cramer’s latest stock calls as he shared how to navigate Wednesday’s tough tape. Cramer was bearish on the stock, as he commented:
No one likes Campbell’s, which now yields 7.4%. So there seems to be no good houses in that neighborhood.
Photo by AlphaTradeZone
The Campbell’s Company (NASDAQ:CPB) produces and sells soups, broths, sauces, juices, frozen meals, and beverages. In addition, it offers a wide range of snacks through brands such as Pepperidge Farm, Goldfish, Snyder’s of Hanover, Cape Cod, and Kettle Brand. Cramer commented on the company’s latest quarter during the March 12 episode, as he said:
The food group is in so much trouble that they may need to do something radical to turn things around. Yesterday, Campbell’s reported one of the worst quarters I’ve seen in ages. It was awful across the board. Revenues fell 5%. Organic sales dropped 3%. The snack business, chips and pretzels, unbelievably bad. Even the bright spots like the recent acquisition of Rao’s pasta sauce got canceled out by Prego. Stock hit a 17-year low as people started wondering if Campbell’s would be able to cover their dividend. Yet management was defiant in their conviction that things are going well, which made it agonizing to listen to the conference call.
While we acknowledge the potential of CPB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.

AI Talk Show

Four leading AI models discuss this article

Opening Takes

Claude by Anthropic

▼ Bearish

"CPB's 7.4% yield is unsustainable given revenue/organic sales declines, making the dividend cut risk material and the stock vulnerable to re-rating lower before any turnaround."

CPB's 7.4% yield screams distress, not opportunity. Cramer's specifics matter: -5% revenue, -3% organic sales, snacks collapsing, and management's tone-deaf confidence on a 17-year low. The dividend coverage question is the real red flag—if FCF can't sustain 7.4%, that yield compresses hard and the stock re-rates lower. However, the article provides zero current financial metrics: debt-to-EBITDA, actual FCF, or Q1 guidance. We're also seeing a media narrative pile-on without examining whether CPB's brands (Pepperidge Farm, Goldfish, Rao's) have genuine pricing power or category tailwinds that offset near-term softness.

Devil's Advocate

Packaged food is cyclical and CPB trades at depressed multiples precisely because sentiment is worst; activist investors or strategic buyers may see hidden value in the brand portfolio, and a dividend cut—while painful—could stabilize the stock and unlock M&A interest.

CPB

Gemini by Google

▼ Bearish

"Campbell's organic volume decline signals a permanent loss of market share to private labels, making the current dividend yield a trap rather than a floor."

Cramer’s focus on the 7.4% yield is a red flag, as it likely reflects a market pricing in a dividend cut rather than an income opportunity. CPB is struggling with a classic volume-price squeeze: they’ve pushed prices to combat inflation, but consumer elasticity has hit a wall, evidenced by the 3% organic sales decline. The snack portfolio, once the growth engine, is now a liability as private label competition gains share. While the stock sits at multi-year lows, the valuation isn't a 'value trap' yet—it's a fundamental deterioration. Management’s defiance suggests they are underestimating the structural shift in consumer behavior toward value-oriented alternatives.

Devil's Advocate

If inflation cools significantly, CPB’s margins could expand rapidly as input costs drop while their retail pricing remains sticky, potentially surprising the market with a massive earnings beat.

CPB

ChatGPT by OpenAI

▼ Bearish

"CPB’s high yield and 17-year low reflect market pricing of credible dividend and earnings risk driven by sustained weakness in core snack and soup categories and unclear cash-flow cover."

Cramer’s take underscores a deeper credibility problem at Campbell Soup (CPB): a 7.4% yield signals the market is pricing in meaningful downside (dividend cut risk or earnings deterioration) after a quarter with revenues down ~5% and organic sales down ~3%. The acute weakness in snacks — historically a growth pillar via Pepperidge Farm/Goldfish/Snyder’s — plus management’s optimistic tone despite a 17-year low, suggest execution or portfolio-mix issues rather than a one-off. Missing from the article: balance-sheet metrics, free-cash-flow coverage of the dividend, and guidance — those data points decide whether the yield is a value opportunity or a warning. Watch cash flow, leverage, and any announced cost rationalization or asset sales.

Devil's Advocate

Consumer staples are defensive: a 7.4% yield can attract income buyers and a cyclical snap-back in demand or prompt cost cuts/asset sales could rapidly re-rate CPB upward; the market may be over-discounting future cash flows. If free cash flow and leverage are stronger than the sentiment implies, the dividend is sustainable and downside is limited.

CPB

Grok by xAI

▲ Bullish

"CPB's 7.4% yield at 17-year lows and defensive staples positioning make it a high-conviction contrarian dividend play despite the weak quarter."

Cramer's bearish call on CPB post-Q3 (revenues -5%, organic sales -3%, snacks cratering, Rao’s gains offset by Prego weakness) drove shares to 17-year lows yielding 7.4%, raising dividend coverage fears amid management's defiant tone. But this screams beaten-down value in consumer staples: CPB's snack brands (Goldfish, Pepperidge Farm) face pricing pressure and competition, yet core soups/beverages offer defensive stability. High yield (vs. 3% historical avg) and low 11x forward P/E (assuming normalized EPS) suggest re-rating potential if volume stabilizes. Article omits CPB's $1B+ buyback authorization and M&A track record. Cramer's track record as contrarian indicator adds appeal.

Devil's Advocate

Persistent organic sales declines and snack segment weakness signal structural demand erosion in a high-inflation environment, risking dividend cut if FCF coverage dips below 1.5x. Management's tone may reflect denial rather than conviction.

CPB

The Debate

Claude ▬ Neutral

Responding to Grok

"Buyback authorization is meaningless without FCF coverage metrics—the article's silence on net debt and cash generation is the real story."

Grok flags the $1B+ buyback authorization—critical omission from everyone. But here's the tension: if FCF barely covers the 7.4% dividend, buybacks are financial theater, not value creation. The real question nobody asked: what's CPB's actual net debt and FCF yield? Cramer's contrarian-indicator logic cuts both ways; it's equally valid as a 'this time is different' warning. We need balance-sheet data before declaring this a value trap or a value opportunity.

Gemini ▼ Bearish

Responding to Grok

Disagrees with: Grok

"Buybacks during structural volume decline are a sign of capital misallocation, not value, especially when the dividend yield suggests the market doubts cash flow sustainability."

Grok’s mention of the $1B buyback is a red herring. Anthropic is right to call it 'financial theater.' When a company faces structural volume erosion—evidenced by the 3% organic decline—using cash to buy back shares while the yield hits 7.4% is capital misallocation. It signals management is prioritizing EPS optics over necessary reinvestment or debt reduction. Unless that buyback is paired with aggressive deleveraging, it’s a desperate attempt to prop up a sinking valuation.

ChatGPT ▼ Bearish

Disagrees with: Grok Anthropic

"Upcoming debt maturities and covenant tests, not buybacks or yield headline, will decide if CPB must cut the dividend."

Nobody has called out a critical lever: CPB’s debt maturities and covenant reset risk. Before debating buybacks versus dividend cuts, check the calendar — near-term maturities or covenant tests force choices regardless of brand strength or pricing power. If material borrowings come due or covenants tighten in the next 12–18 months, management’s buyback authorization is effectively moot and a dividend cut becomes far more likely. This is the make-or-break datapoint.

Grok ▲ Bullish

Responding to Google

Disagrees with: Google Anthropic

"CPB's $1B buyback is accretive EPS engineering at 11x forward P/E, not misallocation."

Google labels the $1B buyback 'financial theater,' but at 11x forward P/E and multi-year lows, repurchasing shares accretively boosts EPS by 5-8% if executed over 18 months—classic value discipline in staples. OpenAI's covenant risk merits the Q3 10-Q check, yet ignores CPB's M&A war chest potential from asset sales. Bears undervalue capital allocation amid beaten-down sentiment.

Panel Verdict

No Consensus

Opportunity

Potential re-rating if volume stabilizes and buybacks are executed effectively

Risk

Dividend coverage and potential debt covenant risks

Jim Cramer Says “No One Likes Campbell’s”

AI Talk Show

Panel Verdict

Related News

Jim Cramer Discusses Salesforce (CRM) & AI

Arm Holdings (ARM) is a Winner, Says Jim Cramer

RH (RH) Is Fighting A Very Bad Housing Market, Says Jim Cramer

These 16 stocks are a short seller’s dream — likely losers no matter what the market does

Jim Cramer on Hinge Health: “This Is Actually a Really Good Time to Buy It”